Transcriptomic and genomic analysis on pre-treatment biopsies from patients in the KRYSTAL-1 trial revealed that patients presenting a baseline high expression of squamous cell carcinoma-related genes and STK11/LKB1 co-mutations had a shorter treatment duration with adagrasib (24). This evidence concerns the gene STK11 and squamous cell carcinoma.